2026-10-01 FDA Warning Letter: DesBio/Deseret Biologicals, Inc. Cited for Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
In short: On October 1, 2026, the FDA Center for Drug Evaluation and Research issued Warning Letter 735464 to DesBio/Deseret Biologicals, Inc. (CEO Jake Carter) identifying "CHLA:10M," marketed on desbio.com for chlamydia symptom relief, as an unapproved new drug in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA noted that unapproved OTC products marketed for sexually transmitted infections present a serious public health concern because individuals may forgo timely medical care, risking severe complications including infertility, sepsis, and death. DesBio was directed to submit a written response within 15 business days detailing corrective actions and preventative measures.
Argus analysis
# FDA Warning Letter Analysis: DesBio/Deseret Biologicals, Inc.
**Company and Violation**
DesBio/Deseret Biologicals, Inc., a Utah-based firm, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026, for marketing an unapproved drug product. The product "CHLA:10M" is sold on the company's website as symptom relief for chlamydia infection, with labeling describing symptoms including burning urination, testicular pain, and vaginal discharge. FDA's review of desbio.com identified the product as an unapproved new drug intended to treat a sexually transmitted infection, presenting what the agency characterized as a serious public health concern.
**Regulatory Citations and Implications**
The violations cite sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d) and 355(a)), along with section 201(g)(1) (21 U.S.C. 321(g)(1)). These provisions require that new drugs receive FDA approval before marketing. The product failed to qualify as "generally recognized as safe and effective" (GRASE) for its intended use. FDA noted the product contains Chlamydia trachomatis 10M, which is not listed in the Homeopathic Pharmacopeia of the United States, placing it outside any homeopathic exemption and subjecting it to standard drug approval requirements.
**Response Timeline and Industry Watch Points**
DesBio received fifteen business days from receipt to submit a written response to FDAAdvisory@fda.hhs.gov detailing corrective actions and root cause analysis. Compliance officers in homeopathic and dietary supplement sectors should monitor whether the company removes the product, reformulates claims, or challenges FDA's determination. Peer companies marketing symptom-relief products for infectious diseases face heightened enforcement scrutiny. Warning Letters typically precede seizures or injunctions if violations persist, making product removal or NDA submission the practical compliance pathways.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER DesBio/Deseret Biologicals, Inc. MARCS-CMS 735464 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Jake Carter Recipient Title Chief Executive Officer DesBio/Deseret Biologicals, Inc. 469 West Parkland Drive Sandy , UT 84070 United States practitionersupport@desbio.com (b)(6) Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 735464 To Jake Carter: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://desbio.com/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://desbio.com/ in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusi…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was DesBio/Deseret Biologicals, Inc. cited for?
- The FDA Warning Letter to DesBio/Deseret Biologicals, Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
- When did FDA issue the warning letter to DesBio/Deseret Biologicals, Inc.?
- FDA issued the letter (MARCS-CMS 735464) on 2026-10-01 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to DesBio/Deseret Biologicals, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/desbiodeseret-biologicals-inc-735464-10012026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-10-01 FDA Warning Letter: DesBio/Deseret Biologicals, Inc. Cited for Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-desbio-deseret-biologicals-inc-2026-10-01-unapproved-drug
"2026-10-01 FDA Warning Letter: DesBio/Deseret Biologicals, Inc. Cited for Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-desbio-deseret-biologicals-inc-2026-10-01-unapproved-drug.
Argus HQ Research. "2026-10-01 FDA Warning Letter: DesBio/Deseret Biologicals, Inc. Cited for Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-desbio-deseret-biologicals-inc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_desbio_deseret_biologicals_inc_2026_10_01_unapproved_drug_2026,
title = {2026-10-01 FDA Warning Letter: DesBio/Deseret Biologicals, Inc. Cited for Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-desbio-deseret-biologicals-inc-2026-10-01-unapproved-drug},
note = {Accessed: October 7, 2026}
}